Release of rooperol tetra-acetate from topical bases: In vitro studies using silicone membrane

International Journal of Pharmaceutics

Volumn 161, Issue 2, 1998, Pages 237-243

  Pefile, S C ^a   Smith, E W ^a   Albrecht, C F ^b   Kruger, P B ^b  

^a RHODES UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Gel; Oil in water; Ointment; Polydimethylsiloxane; Rooperol tetra acetate; Water in oil

Indexed keywords

CARBOXYMETHYLCELLULOSE; CETOMACROGOL; CETOSTEARYLIC ALCOHOL; CYTOTOXIC AGENT; LIQUID PARAFFIN; OINTMENT BASE; PARAFFIN; PROPYLENE GLYCOL; ROOPEROL TETRAACETATE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ARTICLE; DIFFUSION COEFFICIENT; DRUG RELEASE; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MATHEMATICS; MEMBRANE TRANSPORT; OINTMENT; PARTITION COEFFICIENT; PRIORITY JOURNAL;

EID: 0032559536     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00358-X     Document Type: Article

References (12)

1. Albrecht C.F., Kruger P.B., Smit B.J., Freestone M., Gouws L., Miller R., van Jaarsveld P.P. The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial. S. Afr. Med. J. 85:1995;861-865.
2. Albrecht C.F., Theron E.J., Kruger P.B. Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral pro-drug for cancer therapy. S. Afr. Med. J. 85:1995;853-860.
3. Barry, B.W., 1993. Dermatological Formulations: Percutaneous Absorption. Marcel Dekker, New York.
4. British Pharmacopoeia, 1988. Office of the British Pharmacopoeial Commission, London, pp. 653, 713.
5. ECETOC, 1993. (European Centre for Ecotoxicology and Toxicology of Chemicals), Percutaneous Absorption, Monogram 20, Brussels, p. 20.
6. Guy, R.H., Hadgraft, J., 1989. Mathematical models of percutaneous absorption. In: Bronaugh, R.L., Maibach, H.I. (Eds.), Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery. Marcel Dekker, New York, pp. 13-17.
7. Hadgraft J., Ridout G. Development of model membranes for percutaneous absorption measurements. I. Isopropyl myristate. Int. J. Pharm. 39:1987;149-156.
8. Pefile S.C., Smith E.W., Kruger P.B., Albrecht C.F. The validation of a new stability-indicating HPLC technique developed for the quantitative analysis of rooperol tetra-acetate. J. Liq. Chrom. 20:1997;3061-3072.
9. Rougier, A., Dupuis, D., Lotte, C., Maibach, H.I., 1989. In: Bronaugh, R.L., Maibach, H.I. (Eds.), Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery. Marcel Dekker, New York, p. 425.
10. Smit B.J., Albrecht C.F., Liebenberg R.W., Kruger P.B., Freestone M., Gouws L., Theron E., Bouic P.J.D., Etsebeth S., van Jaarsveld P.P. A phase I trial of hypoxoside as an oral pro-drug for cancer therapy-absence of toxicity. S. Afr. Med. J. 85:1995;865-870.
11. Smith E.W., Haigh J.M. In vitro diffusion cell design and validation. I. A stability- indicating high-performance liquid chromatographic assay for betamethasone 17-valerate in purified isopropyl myristate receptor phase. Pharm. Res. 6:1989;431-435.
12. Twist, J.N., Zatz, J.L., 1989. Interaction of vehicles with model skin membranes in permeation process. In: Bronaugh, R.L. and Maibach, H.I. (Eds.), Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery, Marcel Dekker, New York, pp. 147-148.